Bertrand Tombal, MD, PhD, Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium, discusses optimizing the management of patients with metastatic hormone sensitive prostate cancer (mHSPC) via monitoring patients and the toxicities associated with treatment. This interview took place at the EAU congress in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
